Exonicus
VR combat trauma simulator trusted by DoD and NATO.
Latest event found: 31 Dec 2025 · 10 months ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Exonicus is moving from defense-medical R&D toward international commercialization of its MilExTS XR trauma-training platform, supported by NATO, U.S. military, European defense relationships, and Ukrainian deployment. The company remains small and privately self-funded, with growth dependent on converting pilots, funded programs, and procurement opportunities into recurring contracts.
Efficiency Ratio
The company shows strong technical and operational output relative to its 11–50-person scale, but its reported 2025 loss indicates that commercialization has not yet translated into efficient financial performance.
Evidence Signals
1 negative signalExonicus reported 2025 turnover of €272,068, a net loss of €1,611,256, and equity of €872,805.
Exonicus delivered 50 MilExTS immersive medical-training systems to Ukraine, supporting more than 500 users.
Exonicus reported active relationships across U.S. defense, NATO, and European organizations, including 12 ongoing pilots and more than 100 product-sale requests.
Exonicus reported that its MilExTS platform was deployed in Ukraine with 50 systems supporting more than 500 users.